Reply to the letter to the editor by Rao by Lloyd, Thomas R.




I read with interest the article by Cowley et al. [1] on
transcatheter closure of Fontan fenestrations with the Am-
platzer. In the introduction section, they state that there are
a variety of transcatheter methods to close the fenestrations
and mention clamshell device, Rashkind ductal umbrella,
coil, and Amplatzer septal occluder. I would like to draw the
attention of the readers to our reported experience [2] in
transcatheter inverted buttoned device occlusion of atrial
defects producing right-to-left shunt associated with previ-
ously operated complex congenital cardiac anomalies. Four
of the 12 patients in that report were Fontan fenestrations.
Increase in arterial oxygen saturation, pulmonary-to-sys-
temic flow ratio, and system venous saturation occurred
without a significant change in heart rate, cardiac index, and
systemic oxygen transport. At follow-up 126 5 months
after the procedure, the arterial oxygen saturation remained
improved for the group as a whole. In the four patients in
whom we closed the Fontan fenestrations, the oxygen sat-
urations remained high and no residual shunt was detected
by Doppler studies. A larger experience with 22 patients,
reported in an abstract form [3], confirms the previous
observations [2].
I might take this opportunity to comment on other
issues pertaining to device closure. The single-strand
component of the inverted buttoned device goes onto the
left atrial side of the baffle and is unlikely to interfere
with the function of the atrioventricular valve such as that
reported by Cowley et al. [1] with Amplatzer device.
With the advent and wide use of staged Fontan con-
cept, i.e., bidirectional Glenn initially, followed by di-
version of the inferior vena caval blood into the pulmo-
nary artery either by an intra-atrial tunnel or an
extracardiac conduit (total cavopulmonary connection),
we find it extremely unusual to require a fenestrated
Fontan. Consequently, the need for closure of these fen-
estrations became less.
Finally, the seminal observation that implantation of Am-
platzer septal occluder is feasible, safe, and effective in
occluding Fontan fenestration has already been made by
Tofeig et al. [4], and the current report by Cowley et al. [1]
adds little to our existing knowledge. However, the number
of patient in the series by Cowley et al. [1] (n5 12) is
slightly larger than those of Tofeig et al. [4] (n5 5). The
complication rate is also higher in Cowley et al. [1].
In summary, inverted buttoned device, ignored by
Cowley et al. [1], is a useful device in closing Fontan
fenestrations, perhaps even with less probability of inter-
ference with atrioventricular valve function than Am-
platzer. The need for performing fenestrated Fontans and
consequently the necessity to transcatheter-occlude them
i becoming less since the wide use of staged total
cavopulmonary connection.
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REPLY TO THE LETTER TO THE EDITOR
BY RAO
We appreciate Rao’s drawing attention to the report by
Tofeig et al. [1], an excellent brief description of fenes-
tration closure by the Amplatzer septal occluder in five
patients. This study was appropriately cited in our article.
However, Rao’s claim that our article [2] adds “little to
our existing knowledge” is at best disingenuous. In ad-
dition to the more detailed and statistically evaluated data
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on hemodynamics and residual shunting and improved
radiation exposure times reported in our study, unique
aspects of this study included transhepatic placement of
five Amplatzer devices and radiographic evidence of
progressive compaction of the device during follow-up.
Most importantly, we reported a previously unrecognized
complication of the device, i.e., tricuspid valve injury,
pointing out the importance of not placing the fenestra-
tion site too close to the atrioventricular valve orifice.
We are familiar with the inverted buttoned device, having
attempted fenestration closure with this device in two pa-
tients in whom snare closure could not be accomplished [3].
Unlike the four patients reported by Rao et al. [4], both our
patients had lateral tunnel Fontans, and the “single-strand
component” referred to by Rao (a 25 mm length of stainless
steel wire wrapped in polyurethane foam) proved to be
problematic. In one patient, with an anterior snare location,
this component was coaxed into a position parallel to the
axis of the baffle and the fenestration was closed. Unlike the
patient reported in the present study, this fenestration was
sufficiently superior that the device could lie in the sulcus
between the baffle and the atrial wall without interfering
with the tricuspid valve. The second patient had a posterior
fenestration, and difficulties with finding a position for the
left atrial component of the device contributed to the deci-
sion to retrieve the device and abandon the procedure. This
fenestration position is near the right inferior pulmonary
vein orifice, and the inferior extent of the baffle sulcus was
insufficient for the occluder to lie parallel to the baffle. To
the extent that the straight occluder lies transversely to the
cylindrical baffle, its arms will be directed into the atrial
wall (or pulmonary vein) and the cavity of the pulmonary
venous atrium, increasing the risks of thrombosis and ar-
rhythmia. Although we are less impressed than Rao with the
inverted buttoned device for Fontan fenestration closure, the
report of Rao et al. [4] remains important because the
procedure-related death of one patient is reported.
Finally, Rao’s assertions regarding the utility of Fon-
tan fenestration deserve comment. Staging of the Fontan
through bidirectional Glenn or hemi-Fontan procedures
has been routine at our institution for over a decade, yet
we continue to find Fontan fenestration useful. An ex-
planation for this difference in philosophy may perhaps
be found in the nature of the Fontan population at our
respective centers. All the Fontan patients in the report
by Rao et al. [4] have left ventricles, with what we would
consider relatively straightforward defects. In contrast,
our Fontan patients tend to have much higher risk anat-
my: 70% of our fenestrated Fontan patients have single
right ventricles, most of whom have hypoplastic left
heart syndrome [5]. It is understandable that a center that
undertakes fewer operations in high-risk patients would
be slower to adopt the staged approach and see less
benefit from fenestration. Certainly a more significant
deterrent to the wider use of any experimental device for
Fontan fenestration occlusion is the recent Humanitarian
Device Exemption approval of the CardioSEAL device
for this indication by the U.S. Food and Drug Adminis-
tration. While we have not yet had occasion to implant a
CardioSEAL device from the transhepatic approach, we
have found it very effective from the femoral approach in
occluding those fenestrations that would otherwise be
favorable for closure with the Amplatzer septal occluder.
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